# **Resource Summary Report**

Generated by FDI Lab - SciCrunch.org on Apr 14, 2025

# Ms I-A I-E BV480 M5/114.15.2

RRID:AB\_2869739 Type: Antibody

#### **Proper Citation**

(BD Biosciences Cat# 566086, RRID:AB\_2869739)

### **Antibody Information**

URL: http://antibodyregistry.org/AB\_2869739

Proper Citation: (BD Biosciences Cat# 566086, RRID:AB\_2869739)

Target Antigen: I-A/I-E

**Host Organism:** rat

**Clonality:** monoclonal

**Comments:** Applications: Flow cytometry

**Antibody Name:** Ms I-A I-E BV480 M5/114.15.2

**Description:** This monoclonal targets I-A/I-E

Target Organism: mouse

**Clone ID:** M5/114.15.2 (aka M5/114)

**Antibody ID:** AB\_2869739

Vendor: BD Biosciences

Catalog Number: 566086

**Alternative Catalog Numbers: 566088** 

**Record Creation Time:** 20231110T031930+0000

Record Last Update: 20240725T053841+0000

### **Ratings and Alerts**

No rating or validation information has been found for Ms I-A I-E BV480 M5/114.15.2.

No alerts have been found for Ms I-A I-E BV480 M5/114.15.2.

#### Data and Source Information

Source: Antibody Registry

### **Usage and Citation Metrics**

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at FDI Lab - SciCrunch.org.

Zohaib Ali M, et al. (2024) A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides. eLife, 13.

Deng Q, et al. (2024) SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer cell.

Linde IL, et al. (2023) Neutrophil-activating therapy for the treatment of cancer. Cancer cell, 41(2), 356.

Dutt TS, et al. (2022) Mucosal exposure to non-tuberculous mycobacteria elicits B cell-mediated immunity against pulmonary tuberculosis. Cell reports, 41(11), 111783.

Dikiy S, et al. (2021) A distal Foxp3 enhancer enables interleukin-2 dependent thymic Treg cell lineage commitment for robust immune tolerance. Immunity, 54(5), 931.

Lam KC, et al. (2021) Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell, 184(21), 5338.